MedWatch

ALK CEO on tablet launch in the US: "We will reach our goal"

The Danish allergy group ALK is well on its way to realizing the goal set for the launch of the tablet vaccine Odactra on the US market, which will be the company's largest market with time.

Foto: ALK/PR

Despite a drop in revenue, the allergy company ALK exited the first quarter with black numbers on the bottom line and results that exceed the company's own and analysts' expectations.

Especially the European tablet business showed improvements, and in the future, the sale of tablets will drive the business in the US, which ALK has big plans for.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier